Myeloma Novel Drug Discovery Ver 1.2
Recruiting now
Conditions studied: Multiple Myeloma
In brief
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.
Key facts
- Study ID
- NCT05968417
- Run by
- Institute of Cancer Research, United Kingdom
- People needed
- 250
- Starts
- 2020-07-22
- Expected to finish
- 2035-02-28
- Last updated by the study team
- 2023-08-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
- Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment
- Participants aged 18 years of age or above
- Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling
You may not qualify if…
- Participants unable to provide consent
- Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory
Where it is running
- The Royal Marsden NHS Foundation Trust — Sutton, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.